News

• Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
  02/25/2021 / 12:30 - GlobeNewswire
•  
• Jounce Therapeutics to Present at Upcoming Investor Conferences in March
  02/23/2021 / 14:00 - GlobeNewswire
•  
• Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
  02/18/2021 / 14:00 - GlobeNewswire
•  
• HOOKIPA Pharma to Participate in Upcoming SVB Leerink Global Healthcare Conference
  02/16/2021 / 13:00 - GlobeNewswire
•  
• Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
  02/12/2021 / 14:00 - GlobeNewswire
•  
• Antios Therapeutics Appoints Patrick T. Higgins to Board of Directors
  02/11/2021 / 13:30 - GlobeNewswire
•  
• Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
  02/10/2021 / 15:00 - GlobeNewswire
•  
• Gilead: Q4 EPS down 42% YoY to $1.23
  02/04/2021 / 22:04 - TeleTrader
•  
• National AIDS Memorial Observes Black History Month with AIDS Memorial Quilt Virtual Exhibition Honoring Black Lives Lost to AIDS
  02/04/2021 / 19:03 - GlobeNewswire
•  
• Wall Street higher premarket ahead of earnings
  02/04/2021 / 10:47 - TeleTrader
•  
• LifeVantage Announces Appointment of Chief Executive Officer
  02/02/2021 / 22:06 - GlobeNewswire
•  
• NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis
  01/21/2021 / 08:08 - GlobeNewswire
•  
• Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
  01/13/2021 / 14:00 - GlobeNewswire
•  
• Gilead holds 25.54% of Galapagos shares
  01/11/2021 / 22:01 - GlobeNewswire
•  
• Remdesivir could work against new COVID strains - Gilead
  01/11/2021 / 15:21 - TeleTrader